checkAd
    Startseite > Aktien > Kinnate Biopharma > Nachrichten
    Kinnate Biopharma
    Aktie
    ISIN: US49705R1059 WKN: A2QHVT SYM: 6KB Land USA
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    2,4600
     
    EUR
    0,00 %
    0,0000 EUR
    Letzter Kurs 02.04.24 Tradegate
    Geldkurs
    03.04.24
    2,3600
     
    EUR
    636 STK
    Briefkurs
    03.04.24
    2,5400
     
    EUR
    587 STK

    Kinnate Biopharma Aktie kaufen

    Kauf
    Verkauf

    Neueste Nachrichten

    KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
    13.03.24 · Business Wire (engl.) · Kinnate Biopharma
    Kinnate Biopharma Inc. verkauft seinen in der Entwicklung befindlichen Pan-RAF-Inhibitor, Exarafenib an Pierre Fabre Laboratories
    04.03.24 · PR Newswire (dt.) · Kinnate Biopharma
    Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories
    01.03.24 · globenewswire · Kinnate Biopharma
    KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
    19.02.24 · Business Wire (engl.) · Kinnate Biopharma
    KNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholders
    16.02.24 · Business Wire (engl.) · Kinnate Biopharma
    Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share
    16.02.24 · globenewswire · Kinnate Biopharma
    Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
    09.11.23 · globenewswire · Kinnate Biopharma
    Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
    18.09.23 · globenewswire · Kinnate Biopharma